Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,548 people get MYL articles and Market Currents by email alert.
Get email alerts on MYL »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
PR Newswire (May 17, 2013)
-
-
-
-
PR Newswire (May 15, 2013)
-
-
PR Newswire (May 2, 2013)
-
PR Newswire (Apr 30, 2013)
-
-
PR Newswire (Apr 22, 2013)
-
-
-
PR Newswire (Apr 9, 2013)
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
Why You Should Hold On To MylanDieter Plas • Thu, Feb 7 -
Obamacare Just Part Of The Mylan StoryDana Blankenhorn • Fri, Nov 9, 2012 -
Mylan: Profit From The Generics Boom With This PharmaCris Frangold • Thu, Nov 8, 2012 -
Generics Will Drive Mylan Higher By 2013Cris Frangold • Fri, Aug 31, 2012
-
-
Mylan: Execution, Valuation Discount Suggest Further Upside AheadAlex Shadunsky • Tue, May 22, 2012 -
-
-
-
-
Mylan: Earnings PreviewZacks Investment Research • Mon, Jul 25, 2011 -
-
Mylan: Earnings PreviewZacks Investment Research • Wed, Apr 27, 2011
-
Diagonal Spread in Mylan Has Bearish BiasoptionMONSTER • Tue, Mar 23, 2010 -
Mylan Strengthens Portfolio With Generic Diabetes DrugsZacks Investment Research • Wed, Mar 17, 2010
-
Earnings Preview: MylanTheflyonthewall • Wed, Oct 28, 2009 -
Earnings Preview: MylanTheflyonthewall • Wed, Jul 29, 2009
-
Mylan: Showing Up DoubtersAllen Phatimer • Mon, Feb 23, 2009
-
-
-
-
-
-
-
-
-
-
Billionaire John Paulson's Top Stock PicksInsider Monkey • Thu, Feb 21
-
-
-
-
-
-
-
-
-
-
-
Mylan Management Discusses Q3 2012 Results - Earnings Call TranscriptThu, Oct 25, 2012
-
Mylan Management Discusses Q2 2012 Results - Earnings Call TranscriptThu, Jul 26, 2012
-
Mylan's CEO Discusses Q1 2012 Results - Earnings Call TranscriptThu, Apr 26, 2012
-
Mylan, Inc. - Analyst/Investor DayTue, Feb 21, 2012
-
Mylan's CEO Discusses Q3 2011 Results - Earnings Call TranscriptWed, Oct 26, 2011
-
Mylan's CEO Discusses Q2 2011 Results - Earnings Call TranscriptWed, Jul 27, 2011
-
Mylan's CEO Discusses Q4 2010 Results - Earnings Call TranscriptThu, Feb 24, 2011
-
Mylan Q3 2010 Earnings Call TranscriptTue, Oct 26, 2010
-
Mylan CEO Discusses Q3 2010 Results - Earnings Call TranscriptTue, Oct 26, 2010
-
Mylan Laboratories Inc. Q1 2010 Earnings Call TranscriptThu, Apr 29, 2010
-
Mylan Inc. Q4 2009 Earnings Call TranscriptMon, Mar 1, 2010
-
Mylan Inc. Q2 2009 Earnings Call TranscriptThu, Jul 30, 2009
-
Mylan Inc. Q1 2009 Earnings Call TranscriptFri, May 1, 2009
-
Mylan Inc. Q3 2008 Earnings Call TranscriptThu, Oct 30, 2008
-
Mylan Inc Q2 2008 Earnings Call TranscriptWed, Aug 6, 2008
-
at CNBC.com (Mon, 8:00AM)
-
at Fox Business (Mon, 7:23AM)
-
PR Newswire (May 17, 2013)
-
at CNBC.com (May 16, 2013)
-
PR Newswire (May 15, 2013)
-
at CNBC.com (May 15, 2013)
-
PR Newswire (May 2, 2013)
-
PR Newswire (Apr 30, 2013)
-
at CNBC.com (Apr 26, 2013)
-
PR Newswire (Apr 22, 2013)
-
PR Newswire (Apr 9, 2013)
-
PR Newswire (Apr 3, 2013)
-
at CNBC.com (Mar 25, 2013)
-
PR Newswire (Mar 18, 2013)
-
PR Newswire (Mar 13, 2013)
-
PR Newswire (Mar 4, 2013)
-
at MarketWatch.com (Feb 28, 2013)
-
PR Newswire (Feb 27, 2013)
MYL vs. ETF Alternatives
Company Description
Long considered a leader in the United States (“U.S.”) generic pharmaceutical market, Mylan has grown into a worldwide pharmaceutical leader and is currently the third largest generic and specialty pharmaceutical company in the world, in terms of revenues. This evolution has taken place through... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, May 21, 12:11 PM Bernstein analyst Aaron Gal says Mylan (MYL -0.4%) could still bid $22/share for Warner Chilcott (WCRX +2.2%) as the latter's "willingness" to accept an all-share deal from Actavis (ACT +0.6%) might bring others to the table. Comment! [Healthcare, M&A]
- Friday, May 17, 2:34 PM Actavis' (ACT +1.5%) pursuit of Warner Chilcott (WCRX +0.5%) may be a way to defend itself from a potential takeovers by Valeant Pharmaceuticals (VRX +2.5%) and Mylan (MYL +2.2%). VRX routinely looks at potential acquisitions, but to date has stayed away from WCRX because of its dwindling pipeline, so a combined ACT/WCRX deal would be out of the picture. And it would be virtually impossible for MYL, with a market value of $11.7B, to buy the combined firm. It already has about $6B in debt and Street estimates put a combined companies near $21B. Comment! [Healthcare, M&A]
- Tuesday, May 14, 1:29 PM Actavis (ACT +1.2%) spikes on reports that the company recently turned away a $15B bid from Mylan (MYL +0.1%). Comment! [Healthcare, On the Move, M&A]
- Wednesday, February 27, 5:18 PM Mylan (MYL) acquires Agila Specialties, a developer, manufacturer and marketer of high-quality generic injectable products, from Strides Arcolab for $1.6B in cash. The acquisition significantly expands MYL's global injectables platform and will provide entry into new high-growth geographic markets. The acquisition is expected to close in Q4 of 2013 should be immediately accretive to earnings. Shares +1.8% AH. 1 Comment [Healthcare, M&A, On the Move]
- Tuesday, January 15, 6:08 AM Looking to offset a patent cliff that could cut sales by up to $2.75B this year, Pfizer (PFE) is among the companies reportedly interested in acquiring Agila Specialties, the injectable-medicines unit of India's Strides Arcolab. Novartis (NVS), Mylan (MYL) and Fresenius (APCVZ) have also been eyeing Agila, which produces cancer treatments and antibiotics, and could be valued at $2B. Comment! [Healthcare, M&A]
- Tuesday, January 31, 2012, 11:21 AM Companies lining up to take a hard look at buying a stake in Turkish drugmaker Mustafa Nevzat Ilac Sanayii in a deal that may value the company at $1B include GSK, LLY, PFE, ABT and MYL. Merrill Lynch reportedly has sent teasers to potential bidders and non-binding bids have begun to arrive; bidding may be done within two months. Comment! [Healthcare, M&A]
-
- View all 0 replies
-
StockViews
Canaccord downgrade $MYL to HOLD. "Catalysts behind us and upside limited". View 2013 as a "transition year" - View all 0 replies
-
Jim Van Meerten
$MYL - 100% Barchart technical buy signals - 8 new highs and up 5.25% in the last month - Relative Strength Index 65.70% - View all 0 replies
-
Jim Van Meerten
$MYL - 96% Barchart technical buy signal - 9 new hgihs and up 6.94% in the last month - Relative Strength Index 67.89% - View all 0 replies
-
Jim Van Meerten
MYL - 96% Barchart technical buy signal - 6 new highs and up 4.48% in the last month - Relative Strength Index 63.0% - View all 0 replies
-
- View all 0 replies
-
Jim Van Meerten
MYL - 96% Barchart technical buy signal - 5 new highs and up 2.89% in the last month - Relative Strength Index 63.03% - View all 0 replies
-
- View all 0 replies
-
John Motyka
I sold MYL prematurely in light of this weeks' action. I continue to Hold my position in MAKO...JDM - View all 0 replies
-
John Motyka
IMUC and LGND moving against down market. Both feature similar paradigm shifting healthcare treatment modalities. Sold MYL for LT gain. - View all 0 replies
LATEST REPLIES